FDA Approves Kenvue's OTC Tylenol-Naproxen Combination Painkiller

The U.S. Food and Drug Administration (FDA) on Friday approved a new over-the-counter pain relief pill from Kenvue (NYSE: KVUE) that combines the active ingredients of Tylenol and the anti-inflammatory drug naproxen. The decision allows for the marketing of a new nonprescription option for pain management, expanding a key product line for the consumer health giant.

Product Details and Approval

The fixed-dose combination pill is approved for adults and children aged 12 and older, offering up to 12 hours of pain relief. According to the FDA's clearance, each pill contains 325 milligrams of acetaminophen (the active ingredient in Tylenol) and 110 milligrams of naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID).

The approved uses for the new product include relief from:

• Headaches and toothaches
• Back pain and muscle aches
• Menstrual cramps
• Minor arthritis pain

Market and Corporate Context

Ad

The approval represents a significant product development for Kenvue, which is in the process of being acquired by Kimberly-Clark Corp. (NYSE: KMB), the maker of Kleenex tissues. Kimberly-Clark agreed last November to purchase Kenvue in a transaction valued at more than $40 billion, which is expected to close this year.

This new product will join the portfolio of the combined company, potentially strengthening its position in the highly competitive over-the-counter analgesic market. The announcement provides a positive catalyst for Kenvue as it moves toward the completion of the acquisition.

Regulatory Backdrop and Legal Challenges

Reuters reported that the FDA's approval aligns with a federal initiative aimed at making more verified safe pharmaceutical drugs available for over-the-counter purchase.

However, the approval comes as Kenvue and its flagship Tylenol brand face ongoing legal scrutiny. The company is defending itself against numerous lawsuits, including one filed by the state of Texas and more than 500 private lawsuits revived by a U.S. appeals court. The suits allege the company failed to warn consumers about a purported, but not scientifically proven, link between Tylenol use during pregnancy and autism.